Ocugen clinical trials we track

Check company identity source

Phase 3 1 trial

TrialDrugs studiedStatusPrimary completion
A Phase 3 Study Of OCU400 Gene Therapy for the Treatment Of Retinitis PigmentosaNCT06388200Sub-Retinal Administration of OCU400-301Active not recruiting2027-02-12Estimated

Phase 2 / 3 1 trial

TrialDrugs studiedStatusPrimary completion
A Phase 2/3 Trial to Assess the Efficacy and Safety of OCU410ST for Stargardt DiseaseNCT05956626OCU410STActive not recruiting2026-09-28Estimated

Drugs in these trials

Names as written in the registry records.

Latest recorded trial changes

Filters
Clear filters

· 4 fields changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Number of participants with change in functional vision in the study eye of RP subjects as assessed by LDNA Measure: Number of participants with change in functional vision in the study eye in Gene Agnostic group as assessed by LDNA. After: Measure: Change in functional vision from baseline to week 52 in pooled analysis when study eyes in treatment group were compared to study eyes in untreated control.

Participant count type changed

Before: Estimated. After: Actual.

Enrollment · participant count changed

Before: 150 participants (planned). After: 140 participants (actual).

Primary completion date changed

Before: 31 Dec 2026. After: 12 Feb 2027.

Check registry source